|
Valero-Lopez G, Carreon-Guarnizo E, Hernandez-Clares R, Iniesta-Martinez F, Jimenez-Veiga J, Moreno-Docon A, Iborra-Bendicho MA, Aznar-Robles E, Hellin-Gil MF, Morales-Ortiz A, Meca-Lallana JE. Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm. Neurologia (Engl Ed). 2020 Jul-Aug;35(6):357-362. doi: 10.1016/j.nrl.2020.06.001. Epub 2020 Jun 8. Erratum In: Neurologia (Engl Ed). 2020 Sep;35(7):541. English, Spanish. PubMed PMID: 32591152; PubMed Central PMCID: PMC7836312.
AÑO: 2020; IF: 3.109
|
32591152
|
Fernandez O, Aladro Y, Arroyo R, Brieva L, Calles-Hernandez MC, Carrascal P, Comabella M, Costa-Frossard L, Eichau S, Garcia-Merino JA, Ginestal R, Gonzalez I, Izquierdo G, Martinez-Gines ML, Meca-Lallana JE, Mendibe-Bilbao MM, Oterino A, Prieto JM, Rio J, Ramio-Torrenta L, Romero-Pinel L, Tellez N, Rodriguez-Antiguedad A. 12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (II). Rev Neurol. 2020 Jun 1;70(11):417-429. doi: 10.33588/rn.7011.2020122. English, Spanish. PubMed PMID: 32436209.
AÑO: 2020; IF: 0.87
|
|
Fernandez O, Aladro Y, Arroyo R, Brieva L, Calles-Hernandez MC, Carrascal P, Comabella M, Costa-Frossard L, Eichau S, Garcia-Merino JA, Ginestal R, Gonzalez I, Izquierdo G, Martinez-Gines ML, Meca-Lallana JE, Mendibe-Bilbao MM, Oterino A, Prieto JM, Rio J, Ramio-Torrenta L, Romero-Pinel L, Tellez N, Rodriguez-Antiguedad A. [12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (I)]. Rev Neurol. 2020 May 16;70(10):379-390. doi: 10.33588/rn.7010.2020121. Spanish. PubMed PMID: 32390131.
AÑO: 2020; IF: 0.87
|
|
Sanchez Martinez I, Cerdan Sanchez M, Lopez Roman J, Iniesta Martinez F, Carreon-Guarnizo E, Meca Lallana JE, Zafrilla Rentero P. Possible Influence of the Route of Treatment Administration on Treatment Adherence in Patients With Multiple Sclerosis. Clin Ther. 2020 May;42(5):e87-e99. doi: 10.1016/j.clinthera.2020.03.005. Epub 2020 Apr 30. PubMed PMID: 32362347.
AÑO: 2020; IF: 3.393
|
|
Barrero F, Mallada-Frechin J, Martinez-Gines ML, Marzo ME, Meca-Lallana V, Izquierdo G, Ara JR, Oreja-Guevara C, Meca-Lallana J, Forero L, Sanchez-Vera I, Moreno MJ; in representation of the MS NEXT study investigators. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. PLoS One. 2020 Apr 2;15(4):e0230846. doi: 10.1371/journal.pone.0230846. eCollection 2020. PubMed PMID: 32240213; PubMed Central PMCID: PMC7117743.
AÑO: 2020; IF: 3.24
|